• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体因子I缺乏症的遗传、分子及功能分析。

Genetic, molecular and functional analyses of complement factor I deficiency.

作者信息

Nilsson Sara C, Trouw Leendert A, Renault Nicolas, Miteva Maria A, Genel Ferah, Zelazko Marta, Marquart Hanne, Muller Klaus, Sjöholm Anders G, Truedsson Lennart, Villoutreix Bruno O, Blom Anna M

机构信息

Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden.

出版信息

Eur J Immunol. 2009 Jan;39(1):310-23. doi: 10.1002/eji.200838702.

DOI:10.1002/eji.200838702
PMID:19065647
Abstract

Complete deficiency of complement inhibitor factor I (FI) results in secondary complement deficiency due to uncontrolled spontaneous alternative pathway activation leading to susceptibility to infections. Current genetic examination of two patients with near complete FI deficiency and three patients with no detectable serum FI and also close family members revealed homozygous or compound heterozygous mutations in several domains of FI. These mutations were introduced into recombinant FI and the resulting proteins were purified for functional studies, while transient transfection was used to analyze expression and secretion. The G170V mutation resulted in a protein that was not expressed, whereas the mutations Q232K, C237Y, S250L, I339M and H400L affected secretion. Furthermore, the C237Y and the S250L mutants did not degrade C4b and C3b as efficiently as the WT. The truncated Q336x mutant could be expressed, in vitro, but was not functional because it lacks the serine protease domain. Furthermore, this truncated FI was not detected in serum of the patient. Structural investigations using molecular modeling were performed to predict the potential impact the mutations have on FI structure. This is the first study that investigates, at the functional level, the consequences of molecular defects identified in patients with full FI deficiency.

摘要

补体抑制因子I(FI)完全缺乏会导致继发性补体缺乏,这是由于不受控制的自发替代途径激活导致易受感染。目前对两名几乎完全缺乏FI的患者、三名未检测到血清FI的患者以及他们的近亲进行的基因检测发现,FI的几个结构域存在纯合或复合杂合突变。将这些突变引入重组FI中,并纯化所得蛋白质用于功能研究,同时使用瞬时转染来分析表达和分泌情况。G170V突变导致一种未表达的蛋白质,而Q232K、C237Y、S250L、I339M和H400L突变影响分泌。此外,C237Y和S250L突变体降解C4b和C3b的效率不如野生型。截短的Q336x突变体在体外可以表达,但由于缺乏丝氨酸蛋白酶结构域而无功能。此外,在该患者的血清中未检测到这种截短的FI。利用分子建模进行了结构研究,以预测这些突变对FI结构的潜在影响。这是第一项在功能水平上研究完全缺乏FI的患者中鉴定出的分子缺陷后果的研究。

相似文献

1
Genetic, molecular and functional analyses of complement factor I deficiency.补体因子I缺乏症的遗传、分子及功能分析。
Eur J Immunol. 2009 Jan;39(1):310-23. doi: 10.1002/eji.200838702.
2
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.与非典型溶血性尿毒症综合征相关的因子I突变不影响因子I在补体调节中的功能。
Mol Immunol. 2007 Mar;44(8):1835-44. doi: 10.1016/j.molimm.2006.10.005. Epub 2006 Nov 7.
3
Molecular characterization of two novel cases of complete complement inhibitor Factor I deficiency.两种新型完全补体抑制剂因子 I 缺乏症的分子特征。
Mol Immunol. 2011 Apr;48(8):1068-72. doi: 10.1016/j.molimm.2011.01.012. Epub 2011 Feb 12.
4
Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I.在非典型溶血性尿毒症综合征中发现的补体因子 I 突变导致因子 I 的分泌或功能改变。
Eur J Immunol. 2010 Jan;40(1):172-85. doi: 10.1002/eji.200939280.
5
Complement factor I in health and disease.补体因子 I 在健康与疾病中的作用。
Mol Immunol. 2011 Aug;48(14):1611-20. doi: 10.1016/j.molimm.2011.04.004. Epub 2011 Apr 29.
6
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.非小细胞肺癌细胞产生一组功能性补体因子I及其可溶性辅因子。
Mol Immunol. 2008 Jan;45(1):169-79. doi: 10.1016/j.molimm.2007.04.025. Epub 2007 Jun 4.
7
Analysis of binding sites on complement factor I that are required for its activity.分析补体因子 I 活性所必需的结合位点。
J Biol Chem. 2010 Feb 26;285(9):6235-45. doi: 10.1074/jbc.M109.097212. Epub 2009 Dec 31.
8
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.与溶血尿毒综合征相关的补体因子I(CFI)突变的特征分析。
Mol Immunol. 2008 Jan;45(1):95-105. doi: 10.1016/j.molimm.2007.05.004. Epub 2007 Jun 26.
9
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.补体因子I的突变易导致非典型溶血性尿毒症综合征的发生。
J Am Soc Nephrol. 2005 Jul;16(7):2150-5. doi: 10.1681/ASN.2005010103. Epub 2005 May 25.
10
Complete factor I deficiency due to dysfunctional factor I with recurrent aseptic meningo-encephalitis.因功能异常的因子 I 导致的完全因子 I 缺乏症,伴复发性无菌性脑膜脑炎。
J Clin Immunol. 2013 Nov;33(8):1293-301. doi: 10.1007/s10875-013-9944-8. Epub 2013 Oct 20.

引用本文的文献

1
High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literature.突尼斯非典型溶血性尿毒症综合征患者中热点补体因子I p.Ile357Met致病变体的高流行率:三例新病例报告及文献综述
Front Immunol. 2025 Aug 14;16:1623432. doi: 10.3389/fimmu.2025.1623432. eCollection 2025.
2
Complete Complement Factor I (CFI) deficiency: a systematic review of forty-nine patients including three novel cases.完全补体因子I(CFI)缺乏症:对49例患者的系统评价,包括3例新病例。
BMC Immunol. 2025 Jul 26;26(1):54. doi: 10.1186/s12865-025-00739-y.
3
Pediatric Immunodeficiency Caused by Complement Classical and Alternative Pathway Defects Due to a Homozygous CFI Variant: A Case Report.
因纯合子CFI变异导致补体经典途径和替代途径缺陷引起的小儿免疫缺陷:一例报告
Cureus. 2025 Apr 7;17(4):e81827. doi: 10.7759/cureus.81827. eCollection 2025 Apr.
4
Rescue of secretion of rare-disease-associated misfolded mutant glycoproteins in UGGT1 knock-out mammalian cells.UGGT1 敲除哺乳动物细胞中罕见病相关错误折叠突变糖蛋白分泌的挽救。
Traffic. 2024 Jan;25(1):e12927. doi: 10.1111/tra.12927.
5
Rescue of secretion of a rare-disease associated mis-folded mutant glycoprotein in knock-out mammalian cells.在基因敲除的哺乳动物细胞中挽救与罕见疾病相关的错误折叠突变糖蛋白的分泌。
bioRxiv. 2023 May 31:2023.05.30.542711. doi: 10.1101/2023.05.30.542711.
6
Rapid genome sequencing identifies novel variants in complement factor I.快速基因组测序鉴定补体因子 I 中的新型变异体。
Cold Spring Harb Mol Case Stud. 2022 Dec 28;8(7). doi: 10.1101/mcs.a006239. Print 2022 Dec.
7
Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature.膜性肾病患者因补体因子I致病突变导致的移植后血栓性微血管病:病例报告及文献复习
Front Immunol. 2022 May 26;13:909503. doi: 10.3389/fimmu.2022.909503. eCollection 2022.
8
Complement Factor I Variants in Complement-Mediated Renal Diseases.补体因子 I 变体在补体介导的肾脏疾病中的作用。
Front Immunol. 2022 May 10;13:866330. doi: 10.3389/fimmu.2022.866330. eCollection 2022.
9
Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank.英国生物库中与黄斑厚度降低和年龄相关性黄斑变性相关的罕见补体因子 I 变异体。
Hum Mol Genet. 2022 Aug 23;31(16):2678-2692. doi: 10.1093/hmg/ddac060.
10
Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.补体抑制因子 CSMD1 调节表皮生长因子受体致癌信号,并使乳腺癌细胞对化疗敏感。
J Exp Clin Cancer Res. 2021 Aug 17;40(1):258. doi: 10.1186/s13046-021-02042-1.